Poor AstraZeneca. The European Patent Office has revoked the European Combination patent for Symbicort, to treat asthma following an appeal from a group of generic manufacturers.
The patent had been due to protect Symbicort in 17 countries until 2012.
However, the drug still has data exclusivity that prevents a generic competitor launching a copy before 2010.
More
No comments:
Post a Comment